Letter: Rifaximin Versus Low FODMAP Diet in IBS: What the Primary Endpoint Does Not Tell Us. Authors' Reply
Aliment Pharmacol Ther
.
2026 Mar;63(6):909-910.
doi: 10.1111/apt.70553.
Epub 2026 Jan 29.
Authors
Kee Huat Chuah
1
,
Qing Yuan Loo
1
,
Audrey Joe Chii Loh
1
,
Jing Yi Leong
1
,
Wah Loong Chan
1
,
Xin Hui Khoo
1
,
Kim Leng Wong
2
,
Sarala Panirsheeluam
2
,
Vicraman Natarajan
2
,
Ai Kah Ng
3
,
Hazreen Abdul Majid
3
4
,
Sanjiv Mahadeva
1
Affiliations
1
Gastroenterology and Hepatology Unit, Department of Medicine, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia.
2
Staff & Student Health Unit, Universiti Malaya Medical Centre, Kuala Lumpur, Malaysia.
3
Centre for Population Health (CePH), Department of Social and Preventive Medicine, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia.
4
School of Health Rehabilitation Sciences, Health Sciences University, Bournemouth, UK.
PMID:
41609062
DOI:
10.1111/apt.70553
No abstract available
Publication types
Letter